Dermatology News and Research

Latest Dermatology News and Research

FDA Dermatology and Ophthalmology Drugs Advisory Committee to review Lux Biosciences’ Luveniq NDA

Lux Biosciences, Inc. today announced that the Dermatology and Ophthalmology Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) is scheduled to review its New Drug Application (NDA) for Luveniq™ (oral voclosporin) for the treatment of non-infectious uveitis involving the intermediate or posterior segments of the eye on June 28, 2010.

12 May 2010

DUSA Pharmaceuticals first-quarter total product revenues up 22%

DUSA Pharmaceuticals, Inc., a dermatology company that is developing and marketing Levulan Photodynamic Therapy (PDT) and other products focused on patients with common skin conditions, reported today its corporate highlights and financial results for the first quarter ended March 31, 2010.

11 May 2010

Forest, Almirall to present data on aclidinium bromide for COPD and LAS100977 for asthma at ATS conference

Forest Laboratories, Inc. and Almirall, S.A. today announced that they are presenting data from several studies of two investigational inhaled respiratory compounds at the annual American Thoracic Society International Conference taking place in New Orleans May 14-19, 2010. Data on aclidinium bromide, an inhaled muscarinic antagonist, which is in Phase III development for COPD, and LAS100977, a long-acting beta 2-agonist, in Phase II development for asthma, will be presented in 11 separate posters.

11 May 2010

Majority of Americans concerned about skin cancer but still like tans

When it comes to tanning, dermatologists have long suspected that most people need an attitude adjustment. Now, results of a new survey by the American Academy of Dermatology (Academy) confirmed that the majority of people still idolize the bronzed look of a tan despite wanting to protect themselves from skin cancer.

10 May 2010

Majority of people like suntan but concerned about skin cancer

10 May 2010

Positive preclinical results of VB-201 for treatment of psoriasis presented at 2010 SID Annual Meeting

VBL Therapeutics today announced positive preclinical results evaluating VB-201 for the treatment of psoriasis. VB-201 is a first-in-class, orally administered immune response modifier expected to reduce inflammation by targeting key pro-inflammatory cytokines. Today's data suggest that VB-201 has significant anti-inflammatory properties that are active against psoriasis; an ongoing Phase 2 efficacy and safety study is currently evaluating VB-201 for the treatment of patients with psoriasis.

7 May 2010

Helix BioMedix reports recorded revenue of $70,000 for first-quarter 2010

Helix BioMedix, Inc., a developer of bioactive peptides, today announced financial results for the company's first quarter 2010 ended March 31, 2010.

7 May 2010

Halozyme Therapeutics first-quarter net loss decreases to $11.8 million

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets, today reported financial results for the first quarter ended March 31, 2010.

7 May 2010

Warner Chilcott reports 209.5% increase in first-quarter 2010 revenues

Warner Chilcott plc today announced its results for the quarter ended March 31, 2010. Revenue in the quarter was $761.3 million, an increase of $515.3 million, or 209.5%, over the prior year quarter.

7 May 2010

DUSA Pharmaceuticals receives notice of allowance for patent covering blue light technology

DUSA Pharmaceuticals, Inc.®, a dermatology company that is developing and marketing Levulan® Photodynamic Therapy (PDT), today announced that the United States Patent and Trademark Office has issued a notice of allowance for a key patent related to its proprietary PDT light source, the BLU-U®, Blue Light Photodynamic Therapy Illuminator.

7 May 2010

New study reveals facial skin cancer occurs predominantly on left-side

In a study appearing in the Journal of the American Academy of Dermatology a Saint Louis University doctor found that facial skin cancers were predominantly on the left-side, and especially in men.

6 May 2010

Merck reports non-GAAP EPS of $0.83 for first-quarter 2010

Merck & Co., Inc. today announced financial results for the first quarter of 2010. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the first quarter of $0.83, which excludes purchase accounting adjustments, merger-related expenses and restructuring costs, as well as a tax charge related to the recently enacted health care reform legislation. First-quarter GAAP EPS was $0.09.

4 May 2010

Skin cancer rates going down in Alberta: Research group

It appears that people are listening to doctors' orders to protect their skin from the sun. In the largest Canadian study of non-melanoma skin cancer, Andrei Metelitsa, Gordon Jung and their research group have found skin cancer rates in Alberta are going down in men and have levelled off for women. This comes at a time when American scientists say that skin cancer rates are on the rise.

4 May 2010

Valeant Pharmaceuticals International reports 30% increase in total revenue for first-quarter 2010

Valeant Pharmaceuticals International today announced first quarter financial results for 2010.

3 May 2010

SARcode presents positive results from Phase 2 study of SAR 1118 ophthalmic solution at Dry Eye Summit

SARcode Corporation, a privately-held biotechnology company focused on developing a novel class of lymphocyte function-associated antigen-1 (LFA-1) antagonists, today announced results of a 230 patient Phase 2 proof-of-concept study evaluating topical SAR 1118 ophthalmic solution in the treatment of aqueous deficient dry eye (keratoconjunctivitis sicca).

3 May 2010

DSM Biologics partners with Australian Governments to build cGMP mammalian CMO

DSM Biologics is pleased to announce the signing of preliminary agreements to enter a partnership with the Australian Governments (Queensland State Government and the Commonwealth of Australia) to design, build and operate the first major Australia-based mammalian biopharmaceutical manufacturing facility, which will be located in Brisbane.

3 May 2010

Hartford, Salt Lake City and Denver outshine other U.S. cities on skin cancer awareness

At first glance, Hartford, Salt Lake City and Denver might not seem to have much in common. But a new survey by the American Academy of Dermatology (Academy) found these three cities outshine other U.S. cities in heeding dermatologists' advice on preventing and detecting skin cancer.

3 May 2010

Celtic Pharma commences enrolment in Phase III trial of TDT 067 for onychomycosis

Celtic Pharmaceutical Holdings L.P., the global private equity firm focused on the biotechnology and pharmaceutical industries, announced today the enrolment of the first patient into its Phase III trial of TDT 067, terbinafine in Transfersomes®, for the topical treatment of onychomycosis (also known as a fungal nail infection).

30 Apr 2010

IRIDEX commences commercial shipment of IQ 532 laser systems

IRIDEX Corporation, today announced the commencement of commercial shipment of the IQ 532 laser systems. The IQ 532 is a high-power, 532 nm, dual port multi-purpose laser system for use by ophthalmologists to treat sight-threatening eye diseases such as diabetic retinopathy, age-related macular degeneration and glaucoma; and for use by otolaryngologists to correct certain types of conductive hearing loss.

30 Apr 2010

Study confirms MammaPrint's capabilities in determining patients likely to benefit from chemotherapy

Today, at the 11th Annual Meeting of the American Society of Breast Surgeons, Agendia, a world leader in molecular cancer diagnostics, announced that Breast Cancer Research and Treatment has published an important study demonstrating the benefit of adjuvant chemotherapy for patients with a high-risk of breast cancer recurrence according to the MammaPrint test. The ASBS meeting takes places April 28 - May 2, 2010, at the Bellagio in Las Vegas, where you can meet the Agendia team at booth # 314.

30 Apr 2010

Dermatology News and Research

Latest Dermatology News and Research

FDA Dermatology and Ophthalmology Drugs Advisory Committee to review Lux Biosciences’ Luveniq NDA

DUSA Pharmaceuticals first-quarter total product revenues up 22%

Forest, Almirall to present data on aclidinium bromide for COPD and LAS100977 for asthma at ATS conference

Majority of Americans concerned about skin cancer but still like tans

Majority of people like suntan but concerned about skin cancer

Positive preclinical results of VB-201 for treatment of psoriasis presented at 2010 SID Annual Meeting

Helix BioMedix reports recorded revenue of $70,000 for first-quarter 2010

Halozyme Therapeutics first-quarter net loss decreases to $11.8 million

Warner Chilcott reports 209.5% increase in first-quarter 2010 revenues

DUSA Pharmaceuticals receives notice of allowance for patent covering blue light technology

New study reveals facial skin cancer occurs predominantly on left-side

Merck reports non-GAAP EPS of $0.83 for first-quarter 2010

Skin cancer rates going down in Alberta: Research group

Valeant Pharmaceuticals International reports 30% increase in total revenue for first-quarter 2010

SARcode presents positive results from Phase 2 study of SAR 1118 ophthalmic solution at Dry Eye Summit

DSM Biologics partners with Australian Governments to build cGMP mammalian CMO

Hartford, Salt Lake City and Denver outshine other U.S. cities on skin cancer awareness

Celtic Pharma commences enrolment in Phase III trial of TDT 067 for onychomycosis

IRIDEX commences commercial shipment of IQ 532 laser systems

Study confirms MammaPrint's capabilities in determining patients likely to benefit from chemotherapy

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Dermatology News and Research

Latest Dermatology News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in